Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

HSL and Teleste collaborate to improve customer experience along Helsinki’s new light rail line

TURKU, FINLAND — October 23, 2023 — Helsingin Seudun Liikenne (HSL) and the technology company Teleste are bringing cutting-edge display technologies to HSL’s new light rail line in Helsinki, Finland, to ensure a seamless and convenient travel experience for passengers. Approximately 150 of Teleste’s information displays have been installed to the stops along the light rail line number 15 to deliver real-time and readily accessible passenger information to users of the line that officially commenced its regular service on October 21. In facilitating smooth and hassle-free travel, these

Eevia Health Plc exhibiting and launching a new sku at a key tradeshow – Supply Side West in Las Vegas

Eevia Health Plc (”Eevia” or ”The Company”) is promoting its organic health ingredients by exhibiting at Supply Side West, a premier nutraceutical tradeshow in Las Vegas, USA between 23 and 27 October 2023Eevia Health Plc exhibiting and launching a new sku at a key tradeshow – Supply Side West in Las Vegas Eevia Health Plc (”Eevia” or ”The Company”) is promoting its organic health ingredients by exhibiting at Supply Side West, a premier nutraceutical tradeshow in Las Vegas, USA between 23 and 27 October 2023 Supply Side West is a key

Interim report third quarter 2023

Third quarter 2023 Strong resilience in the quarter Continuing operations · Order intake SEK 28,927 million (29,231) · Order intake, at fixed exchange rates, declined by 4% · Revenues SEK 31,476 million (29,267) · Revenue growth, at fixed exchange rates 4% · Adjusted EBITA SEK 6,312 million (5,889) · Adjusted EBITA margin 20.1% (20.1.) · Adjusted EBIT SEK 5,815 million (5,519) · Adjusted EBIT margin 18.5% (18.9) · Adjusted profit before tax SEK 5,056 million (5,336) · Profit for the period SEK 3,900 million (3,396) · Adjusted profit for the period

Nominating Committee proposes new Chairman in Axfood

The Nominating Committee of Axfood has decided to propose that Thomas Ekman shall be elected as Chairman of the Board at the Annual General Meeting on 20 March 2024. Mia Brunell Livfors has announced that she is not available for re-election as Chairman of the Board, but as member of the board.- We are very pleased to be able to propose Thomas Ekman as the new Chairman of the Board. Thomas has extensive experience in both company management and board work and was elected as member of the Board of Axfood already at the last annual general meeting. We want to warmly thank Mia Brunell Livfors

Nokian Tyres becomes the main partner of Cross-Country Ski Team Finland while celebrating the 90th anniversary of the winter tire

Nokian Tyres plc Press Release October 23, 2023 at 12 p.m. EEST Nokian Tyres, the expert of winter performance and the inventor of the winter tire, enters into a partnership with the Finnish Ski Association. The Finnish tire company will become the main partner of Cross-Country Ski Team Finland as well as junior Cross-Country Ski Team Finland for the seasons 2023–24 and 2024–25. The company will also be the official partner of the Ruka Nordic and Lahti Ski Games world cup events in Finland. ”Cooperation with Cross-Country Ski Team Finland is a good match to our northern heritage and

Buybacks of shares by H&M during week 42, 2023

Between 16 October 2023 and 20 October 2023 H & M Hennes & Mauritz AB (publ) (LEI code 529900O5RR7R39FRDM42) has repurchased in total 775,000 own B shares (ISIN: SE0000106270) as part of the share buyback programme initiated by the board of directors.The share buybacks form part of the SEK 3.0 billion share buyback programme that H&M announced on 27 September 2023. The share buyback programme, which runs between 27 September 2023 and no later than 31 March 2024, is being carried out in accordance with Regulation (EU) No 596/2014 on market abuse (the Market Abuse Regulation – MAR) and

H&M teams up with Coloreel to bring personalized embroidery to Berlin

The global fashion retailer H&M has joined forces with Coloreel to introduce a pioneering approach to customized embroidery. This new partnership allows customers at the H&M Alexa store in Berlin to personalize their apparel with a myriad of expressive designs.The program marks the start of a new and innovative in-store pilot developed by H&Mbeyond. Customers can select from a diverse library of designs that will be updated on a weekly basis. Coloreel redefines the art of embroidery, offering an unlimited spectrum of colors at the touch of a button. The technology reduces wastewater by a

Invitation to presentation of Eastnine's interim report January-September 2023

Eastnine invites investors, analysts and media to a live presentation of the interim report January-September on Thursday 26 October 2023, at 10.00 (CET). The report is expected to be made public the same day at 07.00 (CET).   Time for the webcast Thursday 26 October 2023, at 10.00 (CET)   Click here  to see the webcast.   Please join the event a few minutes before the presentation begins. An investor presentation will be available at www.eastnine.com 15 minutes before the start of the webcast. A recording of the webcast will

Abstract presented at the 11th Trends in Medical Mycology publicly available

Stockholm, Sweden – October 23, 2023 – Biosergen AB (“Biosergen” or the “Company”), a clinical-stage biotech company specializing in the development of innovative anti-fungal therapies, today announced that the company’s abstract about the drug candidate BSG005, which was presented at the 11th Trends in Medical Mycology, on October 21, 2023, is now publicly availableThe abstract presentation, given by Biosergen’s COO Tine Olesen, laid out that single and multiple dose intravenous infusions of BSG005 were safe in healthy subjects. Adverse events were mild to moderate in severity, the

Secure your spot at BioStock Life Science Fall Summit - tickets are running out!

This Wednesday and Thursday, it is finally time for the 6th annual BioStock Life Science Fall Summit! The packed two-day event will take place LIVE, at Medicon Village in Lund, featuring over 40 life science companies showcasing their projects and innovations to investors and potential partners. The Summit also gives space for panel discussions and live interviews where industry experts and investors will offer their valuable advice and experiences.•                                        Where? Medicon Village, Lund •                                        When? October 25-26, 2023. •

Avinor chooses Telia Norway as its 5G pilot partner

Avinor, the state-owned limited company that operates most of the civil airports in Norway, has chosen to partner with Telia Norway to explore how 5G technologies can be used to digitize and streamline airport operations, while also making them more sustainable. One of the projects will, among other things, trial the use of a 5G-controlled robot to streamline the operation of taxiways and runways. “This is an exciting collaborative project for us, and we are proud to be allowed to contribute our 5G expertise to Avinor and together find out how new mobile technology can create

Notification of managers’ and closely related parties’ transactions with Dampskibsselskabet NORDEN A/S’ shares in connection with share buy-back program

ANNOUNCEMENT NO. 176 - 23 OCTOBER 2023 In connection with the announced share buy-back program in NORDEN, A/S Motortramp continuously sells shares pro rata and the market is to be informed accordingly – see the attached file and announcements nos. 112/23 and 113/23.   Kind regards, Dampskibsselskabet NORDEN A/S   Martin Badsted CFO     For further information: Stig Frederiksen, Head of Investor Relations, tel.: +45 32 71 08 55, e-mail: sfr@norden.com

Dampskibsselskabet NORDEN A/S – weekly report on share buy-back

ANNOUNCEMENT NO. 175 - 23 OCTOBER 2023 On 10 August 2023, NORDEN initiated a share buy-back programme in accordance with Regulation No. 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and Commission Delegated Regulation (EU) 2016/1052, (Safe Harbour regulation). The share buy-back programme runs from 10 August 2023 up to and including no later than 31 October 2023. For details, please see announcement no. 112 of 10 August 2023.   Under the share buy-back programme, NORDEN will purchase shares for up to a total of USD 30 million (approximately DKK 204 million).

BioStock: Chordate Medical’s migraine treatment gets attention at congress

Recently, medtech company Chordate Medical participated in the prominent pain congress Deutsche Schmerzkongress in Mannheim, Germany. During the event, they experienced an increased interest in their migraine treatment Ozilia Migraine. This positive reception is expected to strengthen the company’s ongoing marketing activities in Germany, where they previously also conducted a successful patient study. To find out more about the market introduction in Germany and the highlights from the congress, BioStock contacted the company’s CEO Anders Weilandt.Read the full article at biostock.se:

TOMRA: Mandatory notification of trade

TOMRA's CEO Tove Andersen has today bought 5,550 shares in TOMRA Systems ASA at a price of NOK 85.50 per share. After the transaction, Tove Andersen holds 29,479 shares in TOMRA Systems ASA. Further disclosure details can be found in the attached form. Asker, 23 October 2023 TOMRA Systems ASA For further information, please contact: Daniel Sundahl, Head of Investor Relations, Tel: +47 91 36 18 99 This information is considered to be inside information pursuant to the EU Market Abuse Regulation (EU) No 596/2014 and is subject to the disclosure requirements pursuant to Section

Eevia Health Plc receives a 1 mSEK/94 kEUR sales order for a Bilberry extract product

Eevia Health Plc, (”Eevia” or ”The Company”), has received a 94 kEUR sales order from a European nutraceutical brand owner.The customer is a European brand owner headquartered in Sweden. The customer develops and markets effective herbal dietary supplements, as well as cosmetics in over 50.000 pharmacies, health food shops, and other retail outlets across 36 countries, including China and USA. The sales value to Eevia of this new order is 94 kEUR for Feno-Myrtillus® 1, which is a so-called 5:1 Extract. The product is a Bilberry extract standardized for anthocyanins and is a repeat order.

Wärtsilä Decarbonisation Modelling agreement supports Raízen’s commitment to reducing marine sector’s GHG emissions

Wärtsilä Corporation, Trade press release, 23 October 2023 at 10:00 AM EESTTechnology group Wärtsilä has signed a strategic partnership agreement for Decarbonisation Modelling  with Raízen, a major Brazilian energy company. The agreement focuses on both newbuilding and existing operation upgrade plans. Its aim is to build and implement a fleet-wide decarbonisation plan with a particular interest in the future marine introduction of ethanol as a marine fuel. Wärtsilä, under its fleet decarbonisation programme, has a strong track record in bringing new

Svenska Aerogel sales update: “Intensified focus on Transport and one more customer introducing product with Quartzene[®]”

Svenska Aerogel is intensifying its focus on the Transport industry – this is stated by CEO Tor Einar Norbakk as he gives a new sales update. The company is currently engaged in several ongoing customer projects related to battery safety for electric vehicles, and this is reflected in Svenska Aerogel’s customer segmentation strategy moving forward. Tor Einar Norbakk also provides updates on key customers, including one that has introduced a product incorporating Quartzene[®] and is preparing for launch.Svenska Aerogel has decided to focus on three primary customer segments going forward:

BioStock: Spago Nanomedical's promising cancer therapy approved for phase I/IIa

Spago Nanomedical has achieved a significant milestone in its cancer therapy development journey. The company's drug candidate, 177Lu-SN201, has received approval to initiate the clinical phase I/IIa study, Tumorad-01, in Australia. To fully appreciate this endeavour, BioStock reached out to Spago’s CEO Mats Hansen.Read the interview with Mats Hansen at biostock.se: Spago Nanomedical's promising cancer therapy approved for phase I/IIa - BioStock This is a press release from BioStock -

Nomination Committee of Medivir appointed

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announces that the nomination committee now has been appointed ahead of the Annual General Meeting in May 2024.According to an AGM resolution, the Nomination Committee 2023-2024 should consist of representatives of at least the three largest shareholders at the end of the third quarter of 2023 and the Chairman of the Board. Work on composing the Nomination Committee is now completed, and this year’s Nomination Committee consists of: Karl Tobieson, appointed by Linc ABRichard Torgerson, appointed by Nordea Investment

Michigan Medicine harnesses the power of Sectra's digital pathology solution to enhance patient care and foster collaboration among physicians

Linköping, Sweden and Shelton, CT – October 23, 2023 – International medical imaging IT and cybersecurity company Sectra  (STO: SECT B) announces that the US health and academic center Michigan Medicine is expanding its usage of Sectra’s enterprise imaging solution by including Sectra's module for digital pathology. This will enable their pathologists to review and collaborate around cases, ultimately improving cancer diagnostics in the region.Digital pathology leads to numerous advantages for hospitals, pathologists, and patients. With Sectra’s digital pathology

Circio Holding ASA - Notifation of shareholding

Pursuant to Section 4-2 of the Norwegian Securities Trading Act and the Securities Trading Act Regulations, we hereby disclose the following information on behalf of Atlas Special Opportunities, LLC. Atlas Special Opportunities, LLC ("Atlas") has on 20 October 2023 sold 123 738 shares in Circio Holding ASA. Atlas holds 274,457 shares in Circio, corresponding to 3.83% of the share capital and voting rights in Circio Holding ASA. This information is subject to the disclosure requirements pursuant to section 4 -3 of the Norwegian Securities Trading Act.

Buybacks of shares in ITAB during week 42 2023

During the period between 16 and 20 October 2023, ITAB Shop Concept AB (publ) (”ITAB”) (LEI-code: 2138001H6FCSZBP26351) has repurchased in total 38,417 own ordinary shares (ISIN: SE0015962097) as part of the share buyback program initiated by the Board of Directors in order to optimise the capital structure.The share buybacks form part of the share buyback program in a maximum amount of MSEK 50 that ITAB announced on 28 September 2023. The share buyback program, which runs from 29 September 2023 until 14 May 2024, is being carried out in accordance with the EU Market Abuse Regulation (“MAR”)

Epiroc AB’s Nomination Committee for the Annual General Meeting 2024

Stockholm, Sweden: According to the Instruction for the Nomination Committee adopted by the Annual General Meeting of Epiroc AB, the Nomination Committee should consist of representatives for the four shareholders, directly registered or ownership grouped, controlling the largest number of votes in Epiroc AB that desire to appoint a member. In addition thereto, the Chairman of the Board of Directors shall be a member.The following persons will form the Nomination Committee for the Annual General Meeting 2024. Petra Hedengran - Investor AB (Chair)Joachim Spetz - Swedbank Robur funds

There are no items matching the current filter
There are no more items matching the current filter
Back to top